Vinblastine

Summary

Vinblastine (CHEMBL159) is an approved small molecule (ATC L01CA01) targeting TUBB; indicated across 28 conditions including neoplasm and hodgkins lymphoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01CA01
• Targets: 1 (TUBB)
• Indications: 28 conditions
• Clinical trials: 99
• Chemistry: 811 Da · C46H58N4O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL159
Name	Vinblastine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	13342
ATC	L01CA01
Molecular formula	C46H58N4O9
Molecular weight	811
InChIKey	JXLYSJRDGCGARV-CFWMRBGOSA-N

SMILES: CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O

IUPAC name: methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate

Also known as: NSC-47842, Vinblastina, Vinblastine, [3h]-vinblastine, vinblastine, vinblastin (VBL), vincaleukoblastine, vincaleucoblasine, vinblastin, viblastine, Vinblastin, Vinbllastine

Parent form; salt/anhydrous children: CHEMBL378544

Patent coverage: 103,548 distinct patent families (412,636 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TUBB	tubulin beta class I	Inhibition	9		P07437

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Nuclear receptor ROR-gamma, Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, ATP-binding cassette sub-family C member 4, Thromboxane-A synthase, Menin/Histone-lysine N-methyltransferase MLL, Tubulin, Tubulin, Tubulin, Prostaglandin G/H synthase 1, Amine oxidase [flavin-containing] B, Multidrug resistance-associated protein 1, Cytochrome P450 3A4, ATP-dependent translocase ABCB1, Proteasome Macropain subunit, Proteasome component C5, ATP-dependent translocase ABCB1, Polyunsaturated fatty acid lipoxygenase ALOX15, Proteasome Macropain subunit MB1, ATP-binding cassette sub-family C member 2.

Bioactivity

ChEMBL activities: 26 potent at pChembl ≥ 5 of 51 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TUBB4A	7.16	IC50	70	nM	CHEMBL_ACT_1217712
ABCB1	7	Ki	100	nM	CHEMBL_ACT_1285226
TUBB4A	6.89	IC50	130	nM	CHEMBL_ACT_25553927
TUBB4A	6.7	EC50	200	nM	CHEMBL_ACT_1844115
TUBB4A	6.52	IC50	300	nM	CHEMBL_ACT_1838510
Q6B856	6.22	IC50	600	nM	CHEMBL_ACT_15237788
P02550	6.22	IC50	600	nM	CHEMBL_ACT_609098
PTGS1	6.21	AC50	623.8	nM	CHEMBL_ACT_25205427
Q6B856	6.16	IC50	700	nM	CHEMBL_ACT_754323
TUBB4A	6.13	IC50	740	nM	CHEMBL_ACT_24730056
P02550	5.96	IC50	1100	nM	CHEMBL_ACT_15702075
ABCB1	5.89	Ki	1300	nM	CHEMBL_ACT_1285229
P02550	5.8	IC50	1600	nM	CHEMBL_ACT_5134834
TBXAS1	5.73	IC50	1870	nM	CHEMBL_ACT_7782348
ABCB1	5.7	IC50	2000	nM	CHEMBL_ACT_1183262
ABCB1	5.68	Ki	2100	nM	CHEMBL_ACT_11002745
TUBB4A	5.68	IC50	2100	nM	CHEMBL_ACT_15185287
ABCB1	5.52	Kd	3000	nM	CHEMBL_ACT_11002228
PSMB1	5.37	IC50	4280	nM	CHEMBL_ACT_18537687
PSMB5	5.34	IC50	4580	nM	CHEMBL_ACT_18537721
PSMB2	5.31	IC50	4900	nM	CHEMBL_ACT_18537704
P12530	5.3	IC50	5037	nM	CHEMBL_ACT_7781565
P06795	5.1	IC50	8000	nM	CHEMBL_ACT_11001892
P06795	5.1	IC50	8000	nM	CHEMBL_ACT_1183264
PTGS1	5.03	AC50	9252	nM	CHEMBL_ACT_25206358
ABCB1	5	IC50	10000	nM	CHEMBL_ACT_2049487

Target pathways

Aggregated over 1 target gene(s): TUBB.

Top Reactome pathways

24 total, by targets touching each:

Pathway	Targets	Genes
Cell Cycle	1	TUBB
Disease	1	TUBB
Innate Immune System	1	TUBB
Immune System	1	TUBB
Organelle biogenesis and maintenance	1	TUBB
Regulation of PLK1 Activity at G2/M Transition	1	TUBB
Loss of Nlp from mitotic centrosomes	1	TUBB
Recruitment of mitotic centrosome proteins and complexes	1	TUBB
Loss of proteins required for interphase microtubule organization from the centrosome	1	TUBB
Centrosome maturation	1	TUBB
Recruitment of NuMA to mitotic centrosomes	1	TUBB
Mitotic G2-G2/M phases	1	TUBB
Cilium Assembly	1	TUBB
Anchoring of the basal body to the plasma membrane	1	TUBB
Infectious disease	1	TUBB
Neutrophil degranulation	1	TUBB
Mitotic Prometaphase	1	TUBB
M Phase	1	TUBB
G2/M Transition	1	TUBB
Cell Cycle, Mitotic	1	TUBB
AURKA Activation by TPX2	1	TUBB
Potential therapeutics for SARS	1	TUBB
SARS-CoV Infections	1	TUBB
Viral Infection Pathways	1	TUBB

Dominant GO biological processes

GO term	Targets
microtubule cytoskeleton organization	1
mitotic cell cycle	1
microtubule-based process	1
cytoskeleton-dependent intracellular transport	1
natural killer cell mediated cytotoxicity	1
regulation of synapse organization	1
spindle assembly	1
cell division	1
odontoblast differentiation	1
cytoskeleton organization	1

Indications & clinical

Indications

13 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
Hodgkins lymphoma	3	MONDO:0004952	EFO:0000183
cutaneous melanoma	3	MONDO:0005012	EFO:0000389
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
leukemia	3	MONDO:0005059	EFO:0000565
lymphoma	3	MONDO:0005062	EFO:0000574
melanoma	3	MONDO:0005105	EFO:0000756
metastatic melanoma	3	MONDO:0005191	EFO:0002617
peripheral T-cell lymphoma, not otherwise specified	3	MONDO:0004964	EFO:0000211
testicular cancer	3	MONDO:0005447	EFO:0004281
lung neoplasm	3	MONDO:0021117	MONDO:0008903
urothelial carcinoma	3	MONDO:0040679	EFO:0008528
skin neoplasm	3	MONDO:0002531	MONDO:0002898

9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Langerhans cell histiocytosis	3	MONDO:0018310	EFO:1000318
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
acute lymphoblastic leukemia	2	MONDO:0004967	EFO:0000220
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
brain neoplasm	2	MONDO:0021211	EFO:0003833
neurofibromatosis type 1	2	MONDO:0018975	MONDO:0018975
paraganglioma	2	MONDO:0000448	EFO:1000453
glioma	2	MONDO:0021042	MONDO:0021637
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 99.

Phase distribution

Phase	Trials
PHASE2	53
PHASE3	26
PHASE1	7
PHASE1/PHASE2	6
PHASE2/PHASE3	2
EARLY_PHASE1	2
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06831370	PHASE4	RECRUITING	A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
NCT02066220	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02205762	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02670707	PHASE3	RECRUITING	Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
NCT04638790	PHASE3	RECRUITING	First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
NCT04685616	PHASE3	RECRUITING	Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT06960577	PHASE3	RECRUITING	Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT00002495	PHASE3	COMPLETED	SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin’s Disease
NCT00002561	PHASE3	COMPLETED	Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin’s Disease
NCT00002855	PHASE3	COMPLETED	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
NCT00002882	PHASE3	COMPLETED	Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
NCT00003027	PHASE3	COMPLETED	Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
NCT00003376	PHASE3	COMPLETED	Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
NCT00003389	PHASE3	COMPLETED	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin’s Lymphoma
NCT00005047	PHASE3	TERMINATED	4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
NCT00005090	PHASE3	TERMINATED	S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin’s Disease
NCT00006237	PHASE3	COMPLETED	S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00024167	PHASE3	TERMINATED	Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
NCT00038558	PHASE3	COMPLETED	Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin’s Disease Receiving ABVD Chemotherapy
NCT00072215	PHASE3	TERMINATED	Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
NCT00264953	PHASE3	COMPLETED	HD11 for Intermediate Stages
NCT00265018	PHASE3	COMPLETED	HD10 for Early Stages
NCT00488605	PHASE3	WITHDRAWN	H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
NCT01134861	PHASE3	COMPLETED	Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT01148446	PHASE3	COMPLETED	R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
NCT01251107	PHASE3	COMPLETED	Study Comparing ABVD vs BEACOPP in Advanced Hodgkin’s Lymphoma
NCT01356680	PHASE3	COMPLETED	HD17 for Intermediate Stage Hodgkin Lymphoma
NCT01712490	PHASE3	COMPLETED	A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
NCT03159897	PHASE3	COMPLETED	FIL Study on ABVD DD-DI as Upfront Therapy in HL.
NCT02840409	PHASE2	ACTIVE_NOT_RECRUITING	Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
NCT02979522	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
NCT03033914	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
NCT03233347	PHASE2	ACTIVE_NOT_RECRUITING	Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
NCT03407144	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03517137	PHASE2	ACTIVE_NOT_RECRUITING	Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
NCT03712202	PHASE2	ACTIVE_NOT_RECRUITING	Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
NCT03755804	PHASE2	ACTIVE_NOT_RECRUITING	Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT05137262	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
NCT05180825	PHASE2	RECRUITING	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
NCT05404945	PHASE2	ACTIVE_NOT_RECRUITING	Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
NCT06164275	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
NCT06377566	PHASE2	RECRUITING	A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
NCT06745076	PHASE2	RECRUITING	Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
NCT06984146	PHASE2	RECRUITING	Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
NCT07013565	PHASE2	RECRUITING	Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
NCT07551583	PHASE2	NOT_YET_RECRUITING	Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
NCT00002715	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Advanced Hodgkin’s Lymphoma
NCT00003084	PHASE2	COMPLETED	Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
NCT00030264	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
NCT00086801	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin’s Lymphoma
NCT00147875	PHASE1/PHASE2	COMPLETED	Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin’s Lymphoma
NCT00186875	PHASE2	COMPLETED	Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00215046	PHASE2	COMPLETED	Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis
NCT00225173	PHASE2	TERMINATED	Combination Chemotherapy +/- Radiation in High Risk Hodgkin’s Disease
NCT00352027	PHASE2	COMPLETED	Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
NCT00369681	PHASE2	COMPLETED	Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
NCT00504504	PHASE2	COMPLETED	Rituximab and ABVD for Hodgkin’s Patients
NCT00512980	PHASE2	TERMINATED	PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
NCT00516750	PHASE2	TERMINATED	Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin
NCT00520403	PHASE2	COMPLETED	A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
NCT00635726	PHASE2	TERMINATED	Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
NCT00654732	PHASE2	COMPLETED	Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
NCT00808639	PHASE2	COMPLETED	Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
NCT00885534	PHASE2	COMPLETED	Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
NCT01285817	PHASE2	COMPLETED	A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
NCT01390584	PHASE2	TERMINATED	Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01468740	PHASE2	UNKNOWN	Prospective Study on HIV-related Hodgkin Lymphoma
NCT01476410	PHASE2	COMPLETED	Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
NCT01542255	PHASE2	TERMINATED	Metronomic Therapy in Patients With Metastatic Melanoma
NCT01639521	PHASE2	WITHDRAWN	Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
NCT01700946	PHASE2	COMPLETED	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
NCT01771107	PHASE1/PHASE2	COMPLETED	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
NCT01887522	PHASE2	TERMINATED	Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
NCT02177695	PHASE2	COMPLETED	S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
NCT02181738	PHASE2	COMPLETED	Study of Nivolumab in Patients With Classical Hodgkin’s Lymphoma (Registrational)
NCT02292979	PHASE2	COMPLETED	Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
NCT02412670	PHASE2	COMPLETED	Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
NCT02414568	PHASE2	COMPLETED	Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
NCT02710734	PHASE2	COMPLETED	Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
NCT03004833	PHASE2	COMPLETED	Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
NCT03331341	PHASE1/PHASE2	COMPLETED	Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
NCT03527628	PHASE2	UNKNOWN	OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
NCT03580408	PHASE2	COMPLETED	Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
NCT03585465	PHASE1/PHASE2	TERMINATED	Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
NCT03646123	PHASE2	TERMINATED	Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
NCT03912818	PHASE2	TERMINATED	Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
NCT05008224	PHASE2	COMPLETED	Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
NCT05062278	PHASE2	UNKNOWN	Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis
NCT00001570	PHASE1	COMPLETED	A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
NCT00498979	PHASE1	COMPLETED	Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
NCT01056679	PHASE1	COMPLETED	Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
NCT01060904	PHASE1	COMPLETED	A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
NCT01135563	PHASE1	COMPLETED	Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
NCT01884922	PHASE1	COMPLETED	Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults
NCT02343718	PHASE1	COMPLETED	Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
NCT06204614	EARLY_PHASE1	ENROLLING_BY_INVITATION	Drug Screening Using IMD in Bladder Cancer
NCT06381570	EARLY_PHASE1	RECRUITING	Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
NCT00187057	Not specified	COMPLETED	Study for Treatment of Cancer in Children With Ataxia-telangiectasia
NCT00187070	Not specified	COMPLETED	Large Cell Lymphoma Pilot Study III

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

17 molecules share ≥1 primary target. Top 17 by shared-target count:

Molecule	Source	Status	Shared targets
PODOFILOX	ChEMBL + PubChem	Phase 4 (approved)	TUBB
COLCHICINE	ChEMBL	Phase 4 (approved)	TUBB
DOCETAXEL	ChEMBL	Phase 4 (approved)	TUBB
LEVOFLOXACIN	ChEMBL	Phase 4 (approved)	TUBB
NOSCAPINE	ChEMBL	Phase 4 (approved)	TUBB
PACLITAXEL	ChEMBL	Phase 4 (approved)	TUBB
TIRBANIBULIN	ChEMBL	Phase 4 (approved)	TUBB
VINCRISTINE	ChEMBL	Phase 4 (approved)	TUBB
VINORELBINE	ChEMBL	Phase 4 (approved)	TUBB
PATUPILONE	ChEMBL	Phase 3	TUBB
ABT-751	ChEMBL	Phase 2	TUBB
DOLASTATIN-10	ChEMBL	Phase 2	TUBB
INDIBULIN	ChEMBL	Phase 2	TUBB
MAYTANSINE	ChEMBL	Phase 2	TUBB
MOLIBRESIB	ChEMBL	Phase 2	TUBB
NOCODAZOLE	ChEMBL	Phase 2	TUBB
PARBENDAZOLE	ChEMBL	Phase 2	TUBB